Loading company
Krystal Biotech, Inc.
KRYS · Nasdaq · ·
Next earnings: November 2, 2026
$334.94-0.7%Sep 29 close
- 1M
- -4.7%
- 6M
- +35.6%
- 1Y
- +89.7%
- 5Y
- +481.7%
KRYS · Nasdaq · ·
Next earnings: November 2, 2026
$334.94-0.7%Sep 29 close
Krystal Biotech, Inc. is scheduled to report next on November 2, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $119.2M | $96M | +24.14% |
| Profit | $54.8M | $38.3M | +42.87% |
| Profit per share | $1.79 | $1.29 | +38.76% |
| Free Cash Flow | $71.2M | $50.8M | +40.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Krystal Biotech, Inc.’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Krystal Biotech, Inc. has no earnings call transcript available.